Document Type

Oral Presentation

Location

Oxford Conference Center, Oxford MS

Event Website

https://oxfordicsb.org/

Start Date

8-4-2025 11:45 AM

Description

Consumer interest in using botanicals as complementary medicine to help address a variety of health benefits is rooted in the traditional use of botanicals to support for example vision performance, joint health, and mental wellbeing. With increasingly busy lifestyles, consumers are seeking ways to support their mental energy. While caffeine is a widely used nootropic, consumers are wary of consuming too much caffeine and/or it’s associated “caffeine-crash” effects, and therefore looking for plant-based nootropic alternates. Plant-derived nutraceutical research is now on the research agendas in academic and industry settings. At OmniActive Health Technologies, we are helping to address consumer health benefits through innovations using plant-based extracts that helps to sustain the farmer and the environment. This abstract highlights the research and registration strategy of a nootropic extract from Alpinia galanga. Our goal was to specifically address same day mental energy and alertness benefits. Also known as greater galangal, Alpinia galanga has been a routine part of ethnomedicine in Northeast India and Thailand. The rhizome has a rich phytochemistry of phenolic compounds and flavonoids, with antioxidant, anti-inflammatory and central nervous system stimulant benefits. Clinical studies were conducted to confirm its nootropic benefits. Methods to ensure authenticity, active constituents, and standardization markers have been documented. Collectively, these data guided the registration strategy of Alpinia galanga extract, enXtra™ with claims, for example, same-day nootropic support for mental energy and alertness. Mechanistically, antioxidant and neurotransmitter signaling are likely involved. Alpinia galanga is recognized by EFSA, Therapeutic Goods Act of Australia and Health Canada (HC). In the USA, enXtra™ has a self-affirmed GRAS status with structure-function claims. Our registration strategies continue to expand to other geographies.

Publication Date

April 2025

Accessibility Status

Screen reader accessible, Searchable text

Share

COinS
 
Apr 8th, 11:45 AM

Caffeine-free plant-based nootropics: the evolving science and regulatory journey of Alpinia Galanga.

Oxford Conference Center, Oxford MS

Consumer interest in using botanicals as complementary medicine to help address a variety of health benefits is rooted in the traditional use of botanicals to support for example vision performance, joint health, and mental wellbeing. With increasingly busy lifestyles, consumers are seeking ways to support their mental energy. While caffeine is a widely used nootropic, consumers are wary of consuming too much caffeine and/or it’s associated “caffeine-crash” effects, and therefore looking for plant-based nootropic alternates. Plant-derived nutraceutical research is now on the research agendas in academic and industry settings. At OmniActive Health Technologies, we are helping to address consumer health benefits through innovations using plant-based extracts that helps to sustain the farmer and the environment. This abstract highlights the research and registration strategy of a nootropic extract from Alpinia galanga. Our goal was to specifically address same day mental energy and alertness benefits. Also known as greater galangal, Alpinia galanga has been a routine part of ethnomedicine in Northeast India and Thailand. The rhizome has a rich phytochemistry of phenolic compounds and flavonoids, with antioxidant, anti-inflammatory and central nervous system stimulant benefits. Clinical studies were conducted to confirm its nootropic benefits. Methods to ensure authenticity, active constituents, and standardization markers have been documented. Collectively, these data guided the registration strategy of Alpinia galanga extract, enXtra™ with claims, for example, same-day nootropic support for mental energy and alertness. Mechanistically, antioxidant and neurotransmitter signaling are likely involved. Alpinia galanga is recognized by EFSA, Therapeutic Goods Act of Australia and Health Canada (HC). In the USA, enXtra™ has a self-affirmed GRAS status with structure-function claims. Our registration strategies continue to expand to other geographies.

https://egrove.olemiss.edu/icsb/2025_ICSB/Schedule/20